MWNA
BCYC

Marshall Wace North America’s Bicycle Therapeutics BCYC Stock Holding History

Marshall Wace North America’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$726K Buy
+17,458
New +$611K ﹤0.01% 1028
2021
Q2 		– Sell
-91,640
Closed -$2.74M – 1459
2021
Q1 		$2.74M Buy
91,640
+59,073
+181% +$1.52M 0.01% 726
2020
Q4 		$585K Buy
+32,567
New +$629K ﹤0.01% 1052

Other funds holding BCYC

TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Marshall Wace North America's BCYC Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Bicycle Therapeutics (BCYC) in Q3 2021: 17,458 shares worth $726K. The stake represents ﹤0.01% of the portfolio and ranks #1028 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in BCYC as recently as Q1 2021.

Marshall Wace North America first reported a position in BCYC in Q4 2020 and has held it in 3 quarters since. The position peaked at $2.74M in Q1 2021. 69 funds tracked by Wall St. Rank hold BCYC as of Q3 2021.

  • Marshall Wace North America held 17,458 shares of Bicycle Therapeutics worth $726K as of Q3 2021.
  • Bicycle Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Bicycle Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1028 holding.
  • Marshall Wace North America first reported a position in Bicycle Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • Marshall Wace North America's Bicycle Therapeutics position peaked at $2.74M in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.